The Ministry of Health of Russia approved a new, 11 version of temporary methodological recommendations for the prevention, diagnosis and treatment of COVID-19, prepared by leading Russian experts taking into account accumulated scientific data and clinical practice, the press service of the department reports.
The new version of the recommendations has been amended and refined in the sections on etiotropic and pathogenetic treatment of patients. For inpatient patients, the use of human anti- COVID-19 immunoglobulin as a component of any of the antiviral regimens is recommended. For preventative anti-inflammatory therapy of the disease in adults, glucocorticosteroid in the form of a metered-dose powder for inhalation is possible.
In addition, hydroxychloroquine is excluded from the list of possible drugs for the treatment of COVID-19. Recommendations on the peculiarities of providing medical care to patients with diabetes mellitus have also been updated.
The section on the specific prevention of infection in adults is supplemented with information on the vaccines KoviVak and Sputnik Light.
A new version of the methodological recommendations is posted on the official website of the Ministry of Health of Russia (full version and version in infographic format) and sent to the regions for use in practical work.
In the course of working on each version of the methodological recommendations, more than 100 Russian experts of various specialties conducted a thorough analysis of data on the results of research and experience in the use of drugs. According to the results of the analysis, promising and sufficiently studied drugs were approved for use, and drugs that showed relatively low effectiveness were excluded from the list of recommended ones.
On May 6, the Russian Direct Investment Fund announced the registration of a one-component anti-COVID19 vaccine Sputnik Light.
